Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
Authors:
Open Access
- 7 January 2026
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 26 (5) , 497-509
Abstract
No abstract availableKeywords
Funding Information
- National Center for Advancing Translational Sciences (1UL1TR002541-01)
- Harvard Catalyst (1K23AI185318\u201301A1)
- Harvard Catalyst (R01AI179917)
- Harvard Catalyst (1UL1TR002541-01)
- Harvard Catalyst (AI007061)
- National Institute of Allergy and Infectious Diseases (AI007061)
- National Institute of Allergy and Infectious Diseases (R01AI179917)
- National Institute of Allergy and Infectious Diseases (RO1AI042347-29)
- National Institute of Allergy and Infectious Diseases (5-UM1-AI-069412-19)
- National Institutes of Health
- Howard Hughes Medical Institute
- Wellcome Trust (218443/Z/19/Z)
This publication has 29 references indexed in Scilit:
- Protection from killed whole-cell cholera vaccines: a systematic review and meta-analysisThe Lancet Global Health, 2025
- Protection by natural cholera against later episodes of cholera over 10 years of follow-up in Matlab, Bangladesh: a retrospective cohort studyThe Lancet Microbe, 2025
- Predicting Vibrio cholerae infection and symptomatic disease: a systems serology studyThe Lancet Microbe, 2023
- Dissecting serotype-specific contributions to live oral cholera vaccine efficacyProceedings of the National Academy of Sciences, 2021
- Members of the human gut microbiota involved in recovery from Vibrio cholerae infectionNature, 2014
- Reactogenicity of live-attenuated Vibrio cholerae vaccines is dependent on flagellinsProceedings of the National Academy of Sciences, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infantsVaccine, 2007
- Randomized, Controlled Study of the Safety and Immunogenicity of Peru‐15, a Live Attenuated Oral Vaccine Candidate for Cholera, in Adult Volunteers in BangladeshThe Journal of Infectious Diseases, 2005
- Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-upThe Lancet, 1990